Email: gilcova [at] mit . edu
LbL Particles for Immunoengineering
Gil is researching how to use LbL-NPs to specifically and locally deliver immunostimulatory molecules and proteins to advanced serous ovarian cancer. Gil primary focus is on the enhanced delivery of interleukin-12 (IL-12), a potent and toxic proinflammatory cytokine which promotes a Th1 response and is a downstream inducer of interferon-gamma. The delivery of such an agent can aid in the restoration of the cancer immunity cycle wherein a functional anti-tumor response is observed via the reactivation of quiescent/senescent innate and adaptive immune cells.